BOULDER, Colo.--(BUSINESS WIRE)--PanTheryx®, a global nutrition and biotechnology company, today announced the launch of Relesium™, a patented, all-natural supplement formulated to address pervasive gut-related side effects of glucagon-like peptide 1 (GLP-1) medications, including popular weight-loss drugs like Ozempic®, Wegovy®, Mounjaro® and other Semaglutides and Tirzepatides. Relesium combines the scientifically backed benefits of chicken egg powder and bovine colostrum, offering an all-natural solution for companies aiming to address digestive discomfort, such as nausea, acid reflux, bloating, constipation, and diarrhea, experienced by a substantial portion of GLP-1 users worldwide.
With rising GLP-1 use for weight loss, diabetes and other health conditions, one in eight Americans now rely on these drugs, with up to 50% of GLP-1 patients reporting mild to moderate gastrointestinal side effects. This leads many to reduced dosages of the drugs and up to 30% of users to discontinue the treatment, despite the tremendous health benefits. While current recommendations focus on diet modification, such as consuming small, bland meals, many patients seek additional support to manage symptoms effectively without turning to other medications that may interfere with the GLP-1 efficacy.
PanTheryx, the developer of Relesium, is committed to making this gut-health solution widely accessible. “Relesium is entering a largely untapped market addressing a need for an all-natural, fast-acting and patented solution to alleviate the GI discomfort millions worldwide experience with GLP-1 drugs, while also helping to restore the gut microbiome,” said Tom Feeley, CEO of PanTheryx. “This ingredient now allows health and wellness companies to offer their customers a science-backed product that addresses these challenges without compromising the effectiveness of their GLP-1 therapy and additional medications.”
Evidence-based Insights and Promising Findings
A new publication in Nutrients, a leading peer-reviewed journal on human nutrition, has highlighted the potential of Relesium for gut health and GLP-1 patients. Raymond Playford, M.D., PhD, a gastroenterologist and long-standing scientific advisor for PanTheryx, and Professor of Molecular Medicine at the University of West London, authored the article that consolidates the growing body of research on chicken egg powder and bovine colostrum. According to Dr. Playford’s analysis, both ingredients offer significant gut-stabilizing benefits, particularly when used in combination due to their synergistic effects.
Dr. Playford explains that “the combination of egg and bovine colostrum not only supports gut stability but also delivers high-quality protein and essential micronutrients—vitamins, minerals, and antioxidants—particularly important for GLP-1 users who may experience reduced appetite, fatigue, and significant energy loss. It also contains prebiotics, to support a healthy microbiome and several other factors such as immunoglobulins and antimicrobial peptides, that help prevent adhesion of microbes to gut surfaces, inhibit bacterial metabolism, and neutralize toxins and viruses.”
Building on these findings, PanTheryx commissioned an observational pilot study led by Harry Oken, M.D., an internist and Adjunct Professor of Medicine at the University of Maryland and former Chair of the Department of Medicine at Johns Hopkins Howard County Medical Center, and Michael Roizen, M.D., an internist, anesthesiologist and Chief Wellness Officer Emeritus at the Cleveland Clinic, to explore Relesium’s effectiveness among GLP-1 medication patients.
“The rapid improvements observed with Relesium offer a natural remedy and show strong potential to help patients feel better, faster,” said Dr. Harry Oken, lead investigator of the observational pilot study. “By easing gastrointestinal distress and aiding gut health, Relesium enables patients to comfortably and safely take the prescribed dose of GLP-1s in order to achieve their maximum intended benefits.”
Eighteen participants using GLP-1 medications enrolled in the study, ten of which experienced gastrointestinal symptoms and were administered Relesium. Initial results are promising, showing that all ten reported notable improvement and reduction in gut-related symptoms after adding Relesium to their regimen. A placebo-controlled trial is planned to further validate Relesium’s efficacy.
A Legacy of Innovation and Expertise
The launch of Relesium reflects the extensive experience of PanTheryx’s leadership and science teams, who collectively bring decades of knowledge in developing breakthrough health ingredients. Their achievements include the launch of life’sDHA®, a pioneering omega-3 ingredient from Martek Biosciences, now DSM-Firmenich, which became a half a billion dollar revenue brand and sought-after nutrition solution for global manufacturers such as Nestlé, Danone, General Mills, Abbott and Bristol Myers Squibb. With Relesium, the team once again delivers a patented, science-backed product for companies looking to support those taking GLP-1s.
Relesium is launching in powder format, which can be used as a standalone supplement or within other product formulations starting January 2025. Additional formats and formulations are under development for future applications.
To learn more about Relesium or PanTheryx, visit: www.pantheryx.com/relesium.
About PanTheryx®
PanTheryx® is a premier science-based health and nutrition company dedicated to bringing category-leading products and solutions to the human health and wellness markets. From leading cutting-edge research to supplying best-in-class ingredients to commercializing category-leading consumer brands, PanTheryx is dedicated to delivering revolutionary digestive, immune, and microbiome health approaches. The PanTheryx global portfolio of consumer brands includes TruBiotics®, Life’s First Naturals®, and DiaResQ®. For more information, please visit www.pantheryx.com.
